Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Clinical trial NCT04225312 · UNKNOWN
Trial details
- NCT number
- NCT04225312
- Sponsor
- Amsterdam UMC, location VUmc
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-03
- Primary completion
- 2025-03-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.